Kingsford Products Co LLC

With more than 3 million members and nearly $7.5 billion in annual revenue, Blue Shield of California is the state's third largest health plan. Established in 1939 and headquartered in San Francisco, Blue Shield is a nonprofit corporation with approximately 4,500 employees and more than 20 offices throughout California. The company is a subsidiary of The Blue Cross and Blue Shield Association, a trade association for the independent, locally operated Blue Cross and Blue Shield plans. The nearly 40 local member companies of the BCBS Association have provided millions of families with quality, affordable health insurance for more than 70 years. One in three Americans carry Blue Cross and Blue Shield cards. The company is now one of the largest health benefits providers in America, serving more than 95 million people in all regions of the country. Blue Shield of California is located in San Francisco.

Established in 1981, Wind River Systems focuses on the design, development and deployment of device software optimization technology. The company s device software optimization solution can be built on a choice of operating systems with an ecosystem of validated and integrated partner technologies. Key tenets of the company s solutions are the standardization of technologies and processes throughout projects, teams and sites, in addition to the use of open standards to provide companies with the broadest possible choice of tools, technologies and architectures. Industry leaders, including Apple, Hewlett Packard, Boeing, Motorola, NASA and Mitsubishi, deploy Wind River technology in more than 300 million devices worldwide. Wind River Systems is a publicly held company headquartered in Alameda, Calif., with operations throughout the United States, Europe, Canada, the Middle East and Asia.

Exelixis is an integrated drug discovery and development company. The company utilizes cutting-edge genomic, molecular biology and combinatorial chemistry technologies to develop innovative therapies for significant human diseases. Its primary mission is to improve patient care by developing proprietary human therapeutics that target the complex molecular causes of disease. Exelixis has built a research and discovery platform. The Exelixis clinical development pipeline includes compounds in cancer and renal disease. The company s pre-clinical pipeline is comprised of six programs. The pre-clinical oncology programs consist of development candidates that focus on inhibiting kinases. In its pre-clinical metabolic disease programs, Exelixis has developed small molecules that modulate nuclear hormone receptors that implicate various metabolic and cardiovascular disorders. Corporate headquarters are in San Francisco. The research facility is in Portland, Ore.